Home
CHUYÊN ĐỀ
Issue: Số 102, 2022
Article
Đặng Việt Phong: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Published: November 1, 2022
Views: 129
References
1.
1. Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997-4126. doi:10.1093/eurheartj/ ehac262
2.
2.mOrtiz M, Martín A, Arribas F, et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017;38(17):1329-1335. doi:10.1093/eurheartj/ehw230
3.
3. Muser D, Liang JJ, Castro SA, et al. Outcomes with prophylactic use of percutaneous left ventricular assist devices in high-risk patients undergoing catheter ablation of scar-related ventricular tachycardia: A propensity-score matched analysis. Heart Rhythm. 2018;15(10):1500-1506. doi:10.1016/j.hrthm.2018.04.028
4.
4. Køber L, Thune JJ, Nielsen JC, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med. 2016;375(13):1221- 1230. doi:10.1056/NEJMoa1608029
5.
5. Sas B, Ps J, Ce J, Jjv M, Rs G. Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. Heart Br Card Soc. 2018;104(2). doi:10.1136/ heartjnl-2016-310850
6.
6. Arenal Á, Ávila P, Jiménez-Candil J, et al. Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia. J Am Coll Cardiol. 2022;79(15):1441-1453. doi:10.1016/j. jacc.2022.01.050